Quantcast

Spark Therapeutics Leadership to Present at Three Upcoming Healthcare Investor Conferences

June 2, 2014

PHILADELPHIA, June 2, 2014 /PRNewswire/ — Spark Therapeutics, Inc., a late-stage gene therapy company developing treatments for a wide range of rare, debilitating diseases, announced today that company leadership will present at three healthcare investor meetings in June.

    --  2014 Jefferies Global Healthcare Conference, New York City, June 5
        Jeffrey D. Marrazzo, co-founder and CEO of Spark, will present on
        Spark's leadership in the advancement of potentially curative, one-time
        gene therapies.

    --  Jefferies Gene Therapy Summit, Boston, June 16 Marrazzo will present on
        the company's expertise in ophthalmology.

    --  Piper Jaffray GenomeRx Symposium, New York City, June 23Marrazzo will
        present along with Katherine A. High, M.D. and J. Fraser Wright, Ph.D.,
        co-founders and scientific advisors to Spark. The three will participate
        in multiple panels, including discussions of genomic-based
        ophthalmologic treatments and regulatory needs in gene therapy clinical
        development.

About Spark Therapeutics, Inc.

Spark Therapeutics, Inc., is developing curative, one-time gene therapy products with the potential to transform the lives of patients and re-imagine the treatment of debilitating diseases. Spark’s lead gene therapy candidate, for RPE65-related blindness, is currently in Phase 3 clinical trials with the potential to be the first approved gene therapy in the United States, and the first treatment to address the significant unmet needs of patients living with blindness due to inherited retinal dystrophies. Additionally, the company has clinical and preclinical programs in other inherited retinal dystrophies and hematological disorders, and a proprietary manufacturing platform that has successfully supported human gene therapy trials across diverse therapeutic areas and routes of administration. Spark’s founding team includes scientists who led the movement to develop gene therapy as a new treatment paradigm, establishing clinical proof of concept in the eye and liver and contributing key insights to the field that have resulted in a resurgence of industry interest in gene-based medicines. To learn more visit www.sparktx.com.

For information contact:

Jessica Rowlands

Feinstein Kean Healthcare

202-729-4089

jessica.rowlands@fkhealth.com

SOURCE Spark Therapeutics


Source: PR Newswire



comments powered by Disqus